A recent industry analysis highlights that many pharmaceutical manufacturing sites still fail EU GMP Annex 1 inspections despite passing traditional GMP audits. Published on 15 May 2026 by industry analyst Dobrin Kolarov, the report shows that regulators now prioritize real-time
